Jeffrey Y. C. Wong

Jeffrey Y. C. Wong

Auto-generated profile, based on publicly available information

Jeffrey Y. C. Wong

Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2006 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
JWJeffrey Y.C. Wong
Jeffrey Y.C. Wong
ALAn Liu
An Liu
TSTimothy Schultheiss
Timothy Schultheiss
LPLeslie Popplewell
Leslie Popplewell
ASAnthony Stein
Anthony Stein
GSGeorge Somlo
George Somlo
Total body irradiation (TBI) is an important part of bone marrow transplantation conditioning regimens. In TBI, dose escalation is difficult, because of associated normal organ toxicities. A method to deliver a more targeted dose of TBI preferentially to sites of greatest tumor burden is needed to reduce the dose to normal organs, reduce toxicities, and permit dose escalation. The purpose of this study was to evaluate, through a dosimetric analysis, the potential advantages and feasibility of selectively delivering targeted myeloablative doses of radiation to bone and marrow using a recently developed image-guided tomographic intensity-modulated radiation therapy delivery system (helical tomotherapy). Whole-body computed tomography datasets from 3 patients, age 5, 20, and 53 years, were used for treatment planning studies to evaluate 2 targeted TBI strategies: total marrow irradiation (TMI), in which the target region was defined as the skeletal bone, and total marrow and lymphoid irradiation (TMLI), in which the target regions were defined as bone, major lymph node chains, liver, spleen, and sanctuary sites, such as brain. Organ doses and dose distributions were compared with those in conventional TBI. A 1.7- to 7.5-fold reduction in median organ doses was observed with TMI and TMLI compared with conventional TBI. With this more targeted approach, a dose-volume histogram analysis predicted the potential to escalate the dose to bone (and containing marrow) up to 20 Gy, while maintaining doses to normal organs at lower levels than in conventional TBI to 12 Gy. Results were similar for the adult and pediatric patients, indicating that this form of targeted TBI will be applicable to most patients regardless of frame size. TMI to 10 Gy was delivered as part of a tandem transplant regimen to the 53-year-old patient with multiple myeloma. Clinical results confirmed the treatment planning predictions. After TMI, the patient experienced the expected blood count nadir, followed by successful engraftment. Grade 2 nausea and grade 1 emesis occurred only briefly on day 2 of TMI. Skin erythema, oral mucositis, esophagitis, and enteritis were not observed. This report demonstrates the feasibility and potential dosimetric advantages of selectively delivering myeloablative doses of radiation to bone and marrow using an image-guided tomographic intensity-modulated radiation therapy delivery system. Organ doses are substantially lower than those associated with standard TBI and predict the potential to significantly reduce associated toxicities and allow for dose escalation. The results also suggest that this form of targeted TBI may have potential advantages over other forms of targeted TBI, such as radioimmunotherapy or bone-seeking radionuclide therapy. Ongoing clinical trials will define the maximum TMI and TMLI doses achievable and define the potential advantages and limitations of this new approach for patients undergoing hematopoietic stem cell transplantation.

1 January 2009 in International Journal of Radiation Oncology, Biology, Physics
Verified
Journal Article
Closed access
JWJeffrey Y.C. Wong
Jeffrey Y.C. Wong
JRJoseph Rosenthal
Joseph Rosenthal
ALAn Liu
An Liu
TSTimothy Schultheiss
Timothy Schultheiss
SFStephen Forman
Stephen Forman
GSGeorge Somlo
George Somlo

1 January 2013 in International Journal of Radiation Oncology, Biology, Physics
Verified
Journal Article
Closed access
JWJeffrey Y.C. Wong
Jeffrey Y.C. Wong
SFStephen Forman
Stephen Forman
GSGeorge Somlo
George Somlo
JRJoseph Rosenthal
Joseph Rosenthal
ALAn Liu
An Liu
ASAnthony Stein
Anthony Stein

1 December 2009 in Cancer Biotherapy and Radiopharmaceuticals
Verified
Journal Article
Closed access
XCXufeng Chen
Xufeng Chen
PWPatty Wong
Patty Wong
EREric Radany
Eric Radany
JWJeffrey Y.C. Wong
Jeffrey Y.C. Wong
Agents that inhibit histone deacetylases (HDAC inhibitors) have been shown to enhance radiation response. The aim of this study was to evaluate the effects of low, minimally cytotoxic concentrations of the HDAC inhibitor, valproic acid (VPA), on radiation response of colorectal cancer cells. Cell lines LS174T and an isogenic pair of HCT116, which differed only for the presence of wild-type p53, were exposed to ionizing radiation (IR) alone, VPA alone, or the combination. Clonogenic survival, γ-H2AX induction, apoptosis, changes in mitochondrial membrane potential, and mitochondrial levels of p53 and Bcl-2 family proteins were assessed. In vivo studies monitored tumor growth suppression after therapy in mice bearing HCT116/p53+/+ and HCT116/p53−/− tumor xenografts. VPA led to radiosensitization, which was dependent on p53 status. A decrease in clonogenic survival, an increase in apoptosis, and an increase in levels of γ-H2AX were observed after VPA+IR, compared to IR alone, in wild-type p53 cells (LS174T and HCT116/p53+/+), as opposed to p53 null cells (HCT116/p53−/−). Exposure to VPA resulted in enhancement of IR-induced mitochondrial localizations of Bax and Bcl-xL, mitochondrial membrane potential, and cytochrome c release only in wild-type p53 cell lines. VPA also enhanced tumor growth suppression after IR only in wild-type p53 xenografts. These data suggest that VPA may have an important role in enhancing radiotherapy response in colorectal cancer, particularly in tumors with the wild-type p53 genotype.

1 December 2019 in International Journal of Radiation Oncology, Biology, Physics
Verified
Journal Article
Closed access
ASAshwin Shinde
Ashwin Shinde
DYDongyun Yang
Dongyun Yang
PFPaul Frankel
Paul Frankel
ALAn Liu
An Liu
CHChunhui Han
Chunhui Han
JWJeffrey Y.C. Wong
Jeffrey Y.C. Wong

1 April 2006 in Cancer Biotherapy and Radiopharmaceuticals
Verified
Journal Article
Closed access
JWJeffrey Y.C. Wong
Jeffrey Y.C. Wong
DCDavid Z. Chu
David Z. Chu
LWLawrence E. Williams
Lawrence E. Williams
ALAn Liu
An Liu
JZJiping Zhan
Jiping Zhan
ARAndrew A. Raubitschek
Andrew A. Raubitschek
Purpose/Objective: Previous radioimmunotherapy (RIT) clinical trials at this institution with 90Y-labeled cT84.66 anti-CEA (carcinoembryonic antigen) evaluated the antibody conjugated to diethylenetriaminepentaacetic acid (DTPA). The aim of this phase I therapy trial was to evaluate cT84.66 conjugated to the macrocyclic chelate 90Y-DOTA and labeled with 90Y in a comparable patient population. Experimental Design: Patients with metastatic CEA-producing cancers were entered in this trial. If antibody targeting to tumor was observed after the administration of 111In-DTPA cT84.66, the patient then received the therapy infusion of 90Y-DOTA-cT84.66 1 week later. Serial nuclear scans, blood and urine collections, and computed tomography (CT) scans were performed to assess antibody biodistribution, pharmacokinetics, toxicities, and antitumor effects. Results: Thirteen (13) patients were treated in this study. Dose-limiting hematologic toxicity was experienced at initial starting activity levels of 12 and 8 mCi/m2. Subsequent patients received systemic Ca-DTPA at 125 mg/m2 every 12 hours for 3 days post-therapy to allow for a dose escalation to 16 mCi/m2, where hematologic toxicity was observed with an associated maximum tolerated dose (MTD) of 13.4 mCi/m2. Tumor doses ranged from 4.4 to 569 cGy/mCi, which translated to 97–12,500 cGy after a single infusion of 90Y-DOTA-cT84.66. Human antichimeric antibody (HACA) response developed in 8 of 13 patients and prevented additional therapy in 4 patients. Conclusions: This study demonstrates the feasibility of using 90Y-DOTA-cT84.66 for antibody-guided radiation therapy. Immunogenicity of the DOTA-conjugated cT84.66 antibody was not appreciably greater than that observed with 90Y-DTPA-cT84.66 in previous trials. Dose-limiting hematopoietic toxicity with 90Y-DOTA-cT84.66 decreased with Ca-DTPA infusions post-therapy and appears to be comparable to previously published results for 90Y-DTPA-cT84.66. The highest antibody uptake and tumor doses were to small nodal lesions, which supports the predictions from preclinical and clinical data that RIT may be best applied in the minimal tumor burden setting.